Benzyldodecyldimethylammonium-D5 Bromide

Total Page:16

File Type:pdf, Size:1020Kb

Benzyldodecyldimethylammonium-D5 Bromide Benzyldodecyldimethylammonium-d5 Bromide sc-217742 Material Safety Data Sheet Hazard Alert Code Key: EXTREME HIGH MODERATE LOW Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Benzyldodecyldimethylammonium-d5 Bromide STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA FLAMMABILITY1 HEALTH3 HAZARD INSTABILITY1 SUPPLIER Santa Cruz Biotechnology, Inc. 2145 Delaware Avenue Santa Cruz, California 95060 800.457.3801 or 831.457.3800 EMERGENCY ChemWatch Within the US & Canada: 877-715-9305 Outside the US & Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112 SYNONYMS C21-H38-Br, "benzalkonium bromide", "benzenemethanaminium, N-dodecyl-N, N-dimethyl-, bromide", "benzododecinium bromide", "benzyldodecyldimethylammonium bromide", "dimethyl laurylbenzene ammonium bromide", "N-dodecyl-N, N-dimethylbenzenemethanaminium bromide", "Ammonyl Br-1244", "Bacfor BL", Bromek, "Sinnoquat BL-95", Sterinol, "quaternary ammonium compound" Section 2 - HAZARDS IDENTIFICATION CHEMWATCH HAZARD RATINGS Min Max Flammability: 1 Toxicity: 2 Body Contact: 3 Min/Nil=0 Low=1 Reactivity: 1 Moderate=2 High=3 Chronic: 3 Extreme=4 CANADIAN WHMIS SYMBOLS 1 of 8 EMERGENCY OVERVIEW RISK Causes burns. Risk of serious damage to eyes. Harmful in contact with skin and if swallowed. Very toxic to aquatic organisms. POTENTIAL HEALTH EFFECTS ACUTE HEALTH EFFECTS SWALLOWED ! The material can produce chemical burns within the oral cavity and gastrointestinal tract following ingestion. ! Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual. ! Ingestion of acidic corrosives may produce burns around and in the mouth. the throat and esophagus. ! Concentrated solutions of many cationics may cause corrosive damage to mucous membranes and the esophagus. Nausea and vomiting (sometimes bloody) may follow ingestion. ! Concentrated solutions of cationic surfactants may cause destruction of the tissue lining the mouth, throat and gullet, and may cause nausea and vomiting. In sufficient quantity may produce restlessness, confusion, low blood pressure, muscle weakness, collapse, convulsion, labored breathing, blue coloration of the lips and coma. EYE ! The material can produce chemical burns to the eye following direct contact. Vapors or mists may be extremely irritating. ! If applied to the eyes, this material causes severe eye damage. ! Direct eye contact with acid corrosives may produce pain, tears, sensitivity to light and burns. Mild burns of the epithelia generally recover rapidly and completely. ! Many cationic surfactants are very irritating to the eyes at low concentration. Concentrated solutions can cause severe burns with permanent clouding. SKIN ! The material can produce chemical burns following direct contactwith the skin. ! Skin contact with the material may be harmful; systemic effects may resultfollowing absorption. ! The material is not thought to be a skin irritant (as classified using animal models). Abrasive damage however, may result from prolonged exposures. ! Skin contact with acidic corrosives may result in pain and burns; these may be deep with distinct edges and may heal slowly with the formation of scar tissue. ! Open cuts, abraded or irritated skin should not be exposed to this material. ! Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected. INHALED ! The material can cause respiratory irritation in some persons. The body's response to such irritation can cause further lung damage. ! Corrosive acids can cause irritation of the respiratory tract, with coughing, choking and mucous membrane damage. There may be dizziness, headache, nausea and weakness. ! Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled. CHRONIC HEALTH EFFECTS ! Long-term exposure to respiratory irritants may result in disease of the airways involving difficult breathing and related systemic problems. Limited evidence suggests that repeated or long-term occupational exposure may produce cumulative health effects involving organs or biochemical systems. There is some evidence that inhaling this product is more likely to cause a sensitization reaction in some persons compared to the general population. There is limited evidence that, skin contact with this product is more likely to cause a sensitization reaction in some persons compared to the general population. There is some evidence that human exposure to the material may result in developmental toxicity. This evidence is based on animal studies where effects have been observed in the absence of marked maternal toxicity, or at around the same dose levels as other toxic effects but which are not secondary non-specific consequences of the other toxic effects. Long term exposure to high dust concentrations may cause changes in lung function i.e. pneumoconiosis; caused by particles less than 0.5 micron penetrating and remaining in the lung. Chronic intoxication with ionic bromides, historically, has resulted from medical use of bromides but not from environmental or occupational exposure; depression, hallucinosis, and schizophreniform psychosis can be seen in the absence of other signs of intoxication. Bromides may also induce sedation, irritability, agitation, delirium, memory loss, confusion, disorientation, forgetfulness (aphasias), dysarthria, weakness, fatigue, vertigo, stupor, coma, decreased appetite, nausea and vomiting, diarrhoea, hallucinations, an acne like rash on the face, legs and trunk, known as bronchoderma (seen in 25-30% of case involving bromide ion), and a profuse discharge from the nostrils (coryza). Ataxia 2 of 8 and generalised hyperreflexia have also been observed. Correlation of neurologic symptoms with blood levels of bromide is inexact. The use of substances such as brompheniramine, as antihistamines, largely reflect current day usage of bromides; ionic bromides have been largely withdrawn from therapeutic use due to their toxicity. Several cases of foetal abnormalities have been described in mothers who took large doses of bromides during pregnancy. Repeated or prolonged exposure to acids may result in the erosion of teeth, swelling and or ulceration of mouth lining. Irritation of airways to lung, with cough, and inflammation of lung tissue often occurs. Section 3 - COMPOSITION / INFORMATION ON INGREDIENTS NAME CAS RN % benzyldimethyldodecylammonium bromide 7281-04-1 >98 Section 4 - FIRST AID MEASURES SWALLOWED " IF SWALLOWED, REFER FOR MEDICAL ATTENTION, WHERE POSSIBLE, WITHOUT DELAY. " Where Medical attention is not immediately available or where the patient is more than 15 minutes from a hospital or unless instructed otherwise: EYE ! If this product comes in contact with the eyes: " Immediately hold eyelids apart and flush the eye continuously with running water. " Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids. SKIN ! If skin contact occurs: " Immediately remove all contaminated clothing, including footwear " Flush skin and hair with running water (and soap if available). INHALED " If fumes or combustion products are inhaled remove from contaminated area. " Lay patient down. Keep warm and rested. Inhalation of vapors or aerosols (mists, fumes) may cause lung edema. Corrosive substances may cause lung damage (e.g. NOTES TO PHYSICIAN ! For acute or short term repeated exposures to strong acids: " Airway problems may arise from laryngeal edema and inhalation exposure. Treat with 100% oxygen initially. " Respiratory distress may require cricothyroidotomy if endotracheal intubation is contraindicated by excessive swelling. For exposures to quaternary ammonium compounds; " For ingestion of concentrated solutions (10% or higher): Swallow promptly a large quantity of milk, egg whites / gelatin solution. If not readily available, a slurry of activated charcoal may be useful. Avoid alcohol. Because of probable mucosal damage omit gastric lavage and emetic drugs. " For dilute solutions (2% or less): If little or no emesis appears spontaneously, administer syrup of Ipecac or perform gastric lavage. Section 5 - FIRE FIGHTING MEASURES Vapour Pressure (mmHG): Negligible Upper Explosive Limit (%): Not available. Specific Gravity (water=1): Not available Lower Explosive Limit (%): Not available EXTINGUISHING MEDIA " Water spray or fog. " Foam. FIRE FIGHTING " Alert Emergency Responders and tell them location and nature of hazard. " Wear full body protective clothing with breathing apparatus. When any large container (including road and rail tankers) is involved in a fire, consider evacuation by 800 metres in all directions. GENERAL FIRE HAZARDS/HAZARDOUS COMBUSTIBLE PRODUCTS " Combustible. " Slight fire hazard when exposed to heat or flame. Combustion products include: carbon monoxide (CO), carbon dioxide (CO2), hydrogen bromide, nitrogen oxides (NOx), other pyrolysis products typical of burning organic material. FIRE INCOMPATIBILITY ! Avoid contamination with oxidizing agents i.e. nitrates, oxidizing acids,chlorine bleaches, pool chlorine etc. as ignition may result. PERSONAL PROTECTION
Recommended publications
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Successfully Improving Ocular Drug Delivery Using the Cationic Nanoemulsion, Novasorb
    Hindawi Publishing Corporation Journal of Drug Delivery Volume 2012, Article ID 604204, 16 pages doi:10.1155/2012/604204 Review Article Successfully Improving Ocular Drug Delivery Using the Cationic Nanoemulsion, Novasorb Frederic Lallemand,1 Philippe Daull,1 Simon Benita,2 Ronald Buggage,1 and Jean-Sebastien Garrigue1 1 Research and Development Department, Novagali Pharma SA, 1 rue Pierre Fontaine, 91058 Evry Cedex, France 2 The Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, POB 12065, 91120 Jerusalem, Israel Correspondence should be addressed to Jean-Sebastien Garrigue, [email protected] Received 7 September 2011; Accepted 9 November 2011 Academic Editor: Abhijit A. Date Copyright © 2012 Frederic Lallemand et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Topical ophthalmic delivery of active ingredients can be achieved using cationic nanoemulsions. In the last decade, Novagali Pharma has successfully developed and marketed Novasorb, an advanced pharmaceutical technology for the treatment of ophthalmic diseases. This paper describes the main steps in the development of cationic nanoemulsions from formulation to evaluation in clinical trials. A major challenge of the formulation work was the selection of a cationic agent with an acceptable safety profile that would ensure a sufficient ocular surface retention time. Then, toxicity and pharmacokinetic studies were performed showing that the cationic emulsions were safe and well tolerated. Even in the absence of an active ingredient, cationic emulsions were observed in preclinical studies to have an inherent benefit on the ocular surface.
    [Show full text]
  • ( 12 ) United States Patent
    US010131766B2 (12 ) United States Patent (10 ) Patent No. : US 10 , 131, 766 B2 Hazen et al. (45 ) Date of Patent: Nov . 20 , 2018 ( 54 ) UNSATURATED POLYESTER RESIN 6 ,619 ,886 B1 9 /2003 Harrington 6 ,692 , 802 B1 2 / 2004 Nava SYSTEM FOR CURED IN - PLACE PIPING 7 , 135 ,087 B2 11/ 2006 Blackmore et al. 7 ,799 ,228 B2 9 /2010 Bomak et al . (71 ) Applicant : Interplastic Corporation , Saint Paul, 8 , 047, 238 B2 11/ 2011 Wiessner et al . MN (US ) 8 ,053 ,031 B2 11/ 2011 Stanley et al. 8 ,092 ,689 B2 1 / 2012 Gosselin (72 ) Inventors : Benjamin R . Hazen , Roseville , MN 8 , 298 , 360 B2 10 / 2012 Da Silveira et al. 8 ,418 , 728 B1 4 / 2013 Kiest , Jr . (US ) ; David J . Herzog , Maple Grove , 8 ,586 ,653 B2 11 / 2013 Klopsch et al. MN (US ) ; Louis R . Ross, Cincinnati , 8 ,636 , 869 B2 1 / 2014 Wiessner et al . OH (US ) ; Joel R . Weber , Moundsview , 8 ,741 , 988 B2 6 /2014 Klopsch et al. MN (US ) 8 , 877 , 837 B2 11/ 2014 Yu et al. 9 ,068 , 045 B2 6 /2015 Nava et al. 9 ,074 , 040 B2 7 / 2015 Turshani et al. ( 73 ) Assignee : Interplastic Corporation , St. Paul , MN 9 , 150 , 709 B2 10 / 2015 Klopsch et al . (US ) 9 , 207 , 155 B1 12 / 2015 Allouche et al. 9 ,273 ,815 B2 3 / 2016 Gillanders et al. ( * ) Notice : Subject to any disclaimer, the term of this 9 , 371, 950 B2 6 / 2016 Hairston et al. patent is extended or adjusted under 35 9 , 550 , 933 B2 1 /2017 Chatterji et al .
    [Show full text]
  • Pharmacology for Students of Bachelor's Programmes at MF MU
    Pharmacology for students of bachelor’s programmes at MF MU (special part) Alena MÁCHALOVÁ, Zuzana BABINSKÁ, Jan JUŘICA, Gabriela DOVRTĚLOVÁ, Hana KOSTKOVÁ, Leoš LANDA, Jana MERHAUTOVÁ, Kristýna NOSKOVÁ, Tibor ŠTARK, Katarína TABIOVÁ, Jana PISTOVČÁKOVÁ, Ondřej ZENDULKA Text přeložili: MVDr. Mgr. Leoš Landa, Ph.D., MUDr. Máchal, Ph.D., Mgr. Jana Merhautová, Ph.D., MUDr. Jana Pistovčáková, Ph.D., Doc. PharmDr. Jana Rudá, Ph.D., Mgr. Barbora Říhová, Ph.D., PharmDr. Lenka Součková, Ph.D., PharmDr. Ondřej Zendulka, Ph.D., Mgr. Markéta Strakošová, Mgr. Tibor Štark, Jazyková korektura: Julie Fry, MSc. Obsah 2 Pharmacology of the autonomic nervous system ........................................................................ 10 2.1 Pharmacology of the sympathetic nervous system ................................................................... 10 2.1.1 Sympathomimetics ............................................................................................................... 12 2.1.2 Sympatholytics ..................................................................................................................... 17 2.2 Pharmacology of the parasympathetic system ......................................................................... 19 2.2.1 Cholinomimetics .................................................................................................................. 20 2.2.2 Parasympathomimetics ......................................................................................................... 21 2.2.3 Parasympatholytics ..............................................................................................................
    [Show full text]
  • Développement Et Élaboration De Systèmes Innovants Pour La Voie Ophtalmique Roseline Mazet
    Développement et élaboration de systèmes innovants pour la voie ophtalmique Roseline Mazet To cite this version: Roseline Mazet. Développement et élaboration de systèmes innovants pour la voie ophtalmique. Médecine humaine et pathologie. Université Grenoble Alpes, 2019. Français. NNT : 2019GREAV057. tel-02957683 HAL Id: tel-02957683 https://tel.archives-ouvertes.fr/tel-02957683 Submitted on 5 Oct 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSE Pour obtenir le grade de DOCTEUR DE LA COMMUNAUTE UNIVERSITE GRENOBLE ALPES Spécialité : Sciences du médicament Arrêté ministériel : 25 mai 2016 Présentée par Roseline MAZET Thèse dirigée par Denis WOUESSIDJEWE, Professeur, Université Grenoble Alpes et encadrée par Annabelle Gèze, Maître de Conférences, Université Grenoble Alpes Préparée au sein du Département de Pharmacochimie Moléculaire (DPM, UMR CNRS 5063, ICMG FR 2607, Université Grenoble Alpes) dans l'École Doctorale Chimie et Sciences du Vivant (ED 218), Université Grenoble Alpes Développement et élaboration de systèmes innovants pour la voie
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,198,800 B1 K0 (45) Date of Patent: Apr
    US007 198800B1 (12) United States Patent (10) Patent No.: US 7,198,800 B1 K0 (45) Date of Patent: Apr. 3, 2007 (54) COMPOSITIONS AND METHODS (56) References Cited (75) Inventor: Thomas Sai Ying Ko. 4 Licence Road, U.S. PATENT DOCUMENTS Belgrave South, Victoria, 3160 (AU) 3,987,000 A * 10/1976 Gleichenhagen et al. ... 523/111 Y re. - - - 5,041.287 A * 8/1991 Driggers et al. .............. 424,81 (73) Assignee: Thomas Sai Ying Ko, Beijing (CN) 5,632,727 A * 5/1997 Tipton et al. ................. 602/47 5,708,023 A * 1/1998 Modak et al. .... ... 514,494 (*) Notice: Subject to any disclaimer, the term of this 5,725.491 A * 3/1998 Tipton et al. ................. 602/43 patent is extended or adjusted under 35 6,183,770 B1* 2/2001 Muchin et al. ............. 424/448 U.S.C. 154(b) by 781 days. * cited by examiner (21) Appl. No.: 09/717,088 Primary Examiner Sreeni Padmanabhan Assistant Examiner Gina Yu (22) Filed: Nov. 22, 2000 (74) Attorney, Agent, or Firm—Sughrue Mion, PLLC (30) Foreign Application Priority Data (57) ABSTRACT Nov. 23, 1999 (AU) ..................................... PQ4190 Non-aerosol spray-on skin patch compositions as described (51) Int. Cl. comprising at least one Substantially water insoluble film A6DF 3/00 (2006.01) forming agent, at least one film plasticizer agent, at least one AOIN 55/00 (2006.01) water soluble compound, and at least one organic solvent, (52) U.S. Cl. ...................... 424/443; 424/447; 424/448: the composition forming a flexible, porous and physiologi 424/449; 424/78.35: 525/363; 514/887: 514/494; cally compatible skin patch when sprayed on to skin and 602/43; 602/47 allowed to dry.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20100015184Al (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0015184 A1 Tue] (43) Pub. Date: Jan. 21, 2010 (54) METHODS OF MAKING PHARMACEUTICAL Publication Classi?cation COMPONENTS FOR CUSTOMIZED DRUG PRODUCTS (51) Int. Cl. A61K 9/00 (2006.01) (76) Inventor: Stephen M_ Tue], Columbia, SC (52) US. Cl. ...................................................... .. 424/400 (Us) (57) ABSTRACT Correspondence Address: Methods and systems for developing and manufacturing STIPKALA LLC componentized drug product precursor modules that can be 5401 NETHERBY LANE, SUITE 102-A simply assembled to create customized drug products are NORTH CHARLESTON, SC 29420 (US) disclosed. Each module contains components of a ?nal drug product (e.g., active pharmaceutical ingredients, nutritional (21) App1_ NO_; 12/518,311 ingredients, and/or excipients) in a ?xed mixture selected to maximize desired pharmaceutical characteristics (e.g., stabil (22) PCT Filed: Dec_ 13, 2007 ity, manufacturing ef?ciency) and minimize cost. The mod ules can be extensively tested for quality and assembled (86) PCT NO _ PCT M52007 I025 43 0 immediately, or at a later time, in multiple combinations to " customize the ?nal drug product characteristics (e.g., mul § 371 (6X1), tiple active ingredients, doses, ?avor, viscosity, etc.) to meet (2)’ (4) Date: Jun 9, 2009 individual patient/consumer needs and/or preferences While assuring high quality. Permitted combinations may be main . tained in a database to enable networked dru roduct selec Related U's'Apphcatlon Data tion, prescribing, and ordering. Each resulgnrg customized (60) Provisional application No, 60/874,554, ?led on Dec, drug product dose can be labeled to facilitate compliance and 13, 2006.
    [Show full text]
  • Human Hemicornea Model for Drug Transport Testing and Screening of Excipients
    Human Hemicornea Model for Drug Transport Testing and Screening of Excipients Von der Fakultät für Lebenswissenschaften der Technischen Universität Carolo-Wilhelmina zu Braunschweig zur Erlangung des Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) genehmigte D i s s e r t a t i o n Von Gustavo Adolfo Guzman Castro aus Cartagena / Kolumbien 1. Referent: PD Dr. Stephan Reichl 2. Referentin: Professorin Dr. Christel Müller-Goymann eingereicht am: 13.12.2016 mündliche Prüfung (Disputation) am: 05.09.2017 Druckjahr 2017 3 Vorveröffentlichungen der Dissertation Teilergebnisse aus dieser Arbeit wurden mit Genehmigung der Fakultät für Lebenswissenschaften, vertreten durch den Mentor der Arbeit, in folgenden Beiträgen vorab veröffentlicht: Publikationen Hahne M, Zorn-Kruppa M, Guzman G, Brandner JM, Haltner-Ukomado E, Wätzig H, Reichl S (2012) Prevalidation of a human cornea construct as an alternative to animal corneas for in vitro drug absorption studies J Pharm Sci 101(8):2976-2988 Tagungsbeiträge Guzman G, Haltner-Ukomado E (2010) Evaluation of culture conditions of two human corneal cell lines employed for the establishment of a new corneal model to assay drug permeability. DPhG Jahrestagung 2011, 04.10 - 06.10.2011, Braunschweig, Germany (poster presentation) Guzman G, Reichl S, Bock U, Haltner-Ukomado E (2011) Cell culture model of human cornea for evaluation of transcorneal drug transport. 13. Bad Herrenalber Transporter- und Barriere-Tage, 30.05 - 01.06.2011, Bad Herrenalb, Germany (poster presentation) Guzman G, Reichl S, Haltner-Ukomado E (2012) Influence of the Ca2+, osmolarities and buffer solutions at different pH on the human cornea constructs during permeability assays. Controlled Release Society (CRS) Germany Local Chapter Meeting 2012, 29.03 - 30.03.2012, Würzburg, Germany (poster presentation) Guzman G, Reichl S, Bock U, Haltner-Ukomado E (2012) Intrinsic passive diffusion of molecular markers and active compounds through a serum-free Hemicornea model.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,072,750 B2 Garrigue Et Al
    US00907275OB2 (12) United States Patent (10) Patent No.: US 9,072,750 B2 Garrigue et al. (45) Date of Patent: Jul. 7, 2015 (54) USE OF PROSTAGLANDINSF2ALPHIA AND (56) References Cited ANALOGUES FOR THE HEALING OF CORNEAL AND CONUUNCTIVAL LESIONS U.S. PATENT DOCUMENTS 4,599,353 A 7, 1986 Bito et al. ..................... 514,530 (75) Inventors: Jean-Sébastien Garrigue, Verrieres le 4,684,633. A 8/1987 Imagawa et al. ................ 514,78 Buisson (FR); Frédéric Lallemand, 5,321,128 A * 6/1994 Stjernschantz et al. ....... 514/530 5,496,811 A 3/1996 Aviv et al. ....................... 514,78 Fresnes (FR); Philippe Daull, 5,510,383 A 4/1996 Bishop et al. ...... 514,530 Soisy-sur-Seine (FR); Christophe 5,588,559 A 12/1996 Vallet Maset al. ............. 222/92 Baudouin, Paris (FR) 5,688,819 A 11/1997 Woodward et al. ........... 514/357 5,767,153 A 6/1998 Bowman et al. ....... 514,530 5,849,792 A 12/1998 Schneider et al. 514,530 (73) Assignee: SANTEN SAS, Evry (FR) 6,007,826 A 12/1999 Benita et al. ....... ... 424/401 6,011,062 A 1/2000 Schneider et al. 514,530 Notice: Subject to any disclaimer, the term of this 6,225.348 B1 5, 2001 Paulsen et al. ..... 514,530 (*) 6,342,524 B1 1/2002 Hellberg et al. ... 514,530 patent is extended or adjusted under 35 6,344,477 B1 2/2002 Sharif et al. ....... 514,530 U.S.C. 154(b) by 559 days. 7,064,109 B2 6/2006 Luyckx et al.
    [Show full text]
  • WO 2009/059191 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 7 May 2009 (07.05.2009) PCT WO 2009/059191 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K9/08 (2006.01) A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, (21) International Application Number: CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, PCT/US2008/082068 EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, (22) International Filing Date: 3 1 October 2008 (31.10.2008) IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, (25) Filing Language: English MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, (26) Publication Language: English RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW 11/932,191 31 October 2007 (31.10.2007) US (71) Applicant (for all designated States except US): EV¬ (84) Designated States (unless otherwise indicated, for every ERETT LABORATORIES, INC. [US/US]; 29 Spring kind of regional protection available): ARIPO (BW, GH, Street, West Orange, New Jersey 07052 (US). GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), (72) Inventor; and European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, (75) Inventor/Applicant (for US only): GIORDANO, John FR, GB, GR, HR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, [US/US]; 44 Fairway Drive, West Orange, New Jersey NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, 07052 (US).
    [Show full text]
  • ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
    Die vorliegende Publikation ist ein Beitrag des GKV-Arzneimittelindex im Wissenschaftlichen Institut der AOK (WIdO). Uwe Fricke, Judith Günther, Anette Zawinell, Rana Zeidan Anatomisch-therapeutisch-chemische Klassifikation mit Tagesdosen für den deutschen Arzneimittelmarkt ATC-Index mit DDD-Angaben für den deutschen Arzneimittelmarkt Berlin 2013, 12. überarbeitete Auflage Wissenschaftliches Institut der AOK (WIdO) im AOK-Bundesverband GbR Rosenthaler Str. 31, 10178 Berlin Geschäftsführender Vorstand: Jürgen Graalmann, Uwe Deh http://www.aok-bv.de/impressum/index.html Aufsichtsbehörde: Senatsverwaltung für Gesundheit und Soziales Oranienstraße 106, 10969 Berlin Pharmazeutisch-technische Assistenz: Gudrun Billesfeld, Sylvia Ehrle, Sandra Heric, Sabine Roggan, Manuela Steden Datenverarbeitung: Kenan Ajanović, Jana Weiss Redaktionelle Bearbeitung: Manuela Steden Umschlagsgestaltung/Design: Ursula M. Mielke Titelfoto: Ulrich Birtel Nachdruck, Wiedergabe, Vervielfältigung und Verbreitung (gleich welcher Art), auch von Teilen des Werkes, bedürfen der ausdrückli- chen Genehmigung. E-Mail: [email protected] Internet: http://www.wido.de Wissenschaftliche Berater des GKV-Arzneimittelindex Wissenschaftliche Berater des GKV-Arzneimittelindex Prof. Dr. med. Dr. h. c. Björn Lemmer Institut für Experimentelle und Klinische Pharmakologie und Toxikologie Ruprecht-Karls-Universität Heidelberg Maybachstraße 14 68169 Mannheim Prof. Dr. med. Martin J. Lohse Institut für Pharmakologie der Universität Würzburg Versbacher Straße 9 97078 Würzburg Dr. med. Klaus Mengel Höferstr. 15 68199 Mannheim Prof. Dr. med. Gerhard Schmidt Zentrum Pharmakologie und Toxikologie der Universität Göttingen Robert-Koch-Straße 40 37075 Göttingen Prof. Dr. med. Hasso Scholz Institut für Experimentelle und klinische Pharmakologie und Toxikologie Universitäts-Krankenhaus Eppendorf Martinistraße 52 20246 Hamburg 3 Hinweise Hinweise Die vorliegende Publikation ist ein Beitrag des Wissenschaftlichen Instituts der AOK (WIdO) und keine Meinungsäußerung des WHO Collaborating Centre for Drug Statistics Methodology.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0015184A1 Tue (43) Pub
    US 2010.0015184A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0015184A1 Tue (43) Pub. Date: Jan. 21, 2010 (54) METHODS OF MAKING PHARMACEUTICAL Publication Classification COMPONENTS FOR CUSTOMIZED DRUG PRODUCTS (51) Int. Cl. A6IR 9/00 (2006.01) (76) Inventor: Stephen M. Tuel, Columbia, SC (52) U.S. Cl. ........................................................ 424/400 (US) (57) ABSTRACT Correspondence Address: Methods and systems for developing and manufacturing STPKALA LLC componentized drug product precursor modules that can be 5401 NETHERBYLANE, SUITE 102-A simply assembled to create customized drug products are NORTH CHARLESTON, SC 29420 (US) disclosed. Each module contains components of a final drug product (e.g., active pharmaceutical ingredients, nutritional (21) Appl. No.: 12/518,311 ingredients, and/or excipients) in a fixed mixture selected to maximize desired pharmaceutical characteristics (e.g., stabil (22) PCT Fled: Dec. 13, 2007 ity, manufacturing efficiency) and minimize cost. The mod ules can be extensively tested for quality and assembled immediately, or at a later time, in multiple combinations to (86) PCT NO.: PCT/US2007/025430 customize the final drug product characteristics (e.g., mul tiple active ingredients, doses, flavor, Viscosity, etc.) to meet S371 (c)(1), individual patient/consumer needs and/or preferences while (2), (4) Date: Jun. 9, 2009 assuring high quality. Permitted combinations may be main tained in a database to enable networked drug product selec Related U.S. Application Data tion, prescribing, and ordering. Each resulting customized (60) Provisional application No. 60/874,554, filed on Dec. drug product dose can be labeled to facilitate compliance and 13, 2006.
    [Show full text]